Growth prediction in asymptomatic meningiomas: the utility of the AIMSS score

  • Ferran Brugada-BellsolàEmail author
  • Pilar Teixidor Rodríguez
  • Ana Rodríguez-Hernández
  • Roser Garcia-Armengol
  • Manel Tardáguila
  • Antonio González-Crespo
  • Carlos J. Domínguez
  • Jordi M. Rimbau
Original Article - Brain Tumors
Part of the following topical collections:
  1. Brain tumors



Management of asymptomatic meningiomas represents a challenge due to the absence of a solid consensus on which is the best management strategy. There are various known factors predicting meningiomas growth risk. However, the Asian Intracranial Meningioma Scoring System (AIMSS) is the only described score to quantify such risk thus emerging as a potential tool for management decisions. This study aims to validate this score on our series of asymptomatic meningiomas.


We performed a retrospective review of asymptomatic meningiomas diagnosed at our institution between January 2008 and October 2016 and followed by an annual cerebral Magnetic Resonance Imaging (MRI). For each lesion, the AIMSS score was calculated thus classifying them in low (0–2), intermediate (3–6) or high risk (7–11) of rapid growth (>2cm3/year). We investigated the correlation between the expected Average Growth Rate (AGR) according to the score and the one obtained in our study. The mean growth velocity over the different risk groups was also compared.


Overall, 69 asymptomatic meningiomas found incidentally in 46 patients were included in the study; 31 were assigned to the low-risk group, 34 to the intermediate-risk group and 4 to the high-risk group. Attending to the AGR, 0% showed rapid growth in the low-risk group, 12% in the intermediate-risk group, and 25% in the high-risk group. The mean growth velocity showed a significant difference over the different risk groups (p < 0,001).


According to our finding, the AIMSS score is a valid tool to estimate the risk of rapid growth of asymptomatic meningiomas. It is especially useful distinguishing between low- and intermediate-risk meningiomas. This feature would allow physicians to adjust the periodicity of radiological and clinical controls. Adding more known risk factors of rapid growth to the score might improve its predictive capabilities with the high-risk group.


Growth risk Asymptomatic meningioma AIMSS score Risk of rapid growth Average growth rate 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (name of institute/committee) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

For this type of study, formal consent is not required.


  1. 1.
    Chamoun R, Krisht KM, Couldwell WT (2011) Incidental meningiomas. Neurosurg Focus 31(6):E19CrossRefGoogle Scholar
  2. 2.
    Chan RC, Thompson GB (1984) Morbidity, mortality and quality of life following surgery for intracranial meningiomas. A retrospective study in 257 cases. J Neurosurg 60:52–60CrossRefGoogle Scholar
  3. 3.
    Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM (2005) Epidemiology of intracranial meningioma. Neurosurgery 57:1088–1095CrossRefGoogle Scholar
  4. 4.
    Cornu P, Chatellier G, Dagreou F et al (1990) Intracranial meningiomas in elderly patients. Postoperative morbidity and mortality. Factors predictive of outcome. Acta Neurochir 102:98–102CrossRefGoogle Scholar
  5. 5.
    Elhammady MS, Heros RC (2013) Asymptomatic meningiomas. J Neurosurg 119:482–486CrossRefGoogle Scholar
  6. 6.
    Fathi AR, Roelcke U (2013) Meningioma. Curr Neurol Neurosci Rep 13(4):337CrossRefGoogle Scholar
  7. 7.
    Hashiba T, Hashimoto N, Izumoto S et al (2009) Serial volumetric assessment of the natural history and growth pattern of incidentally discovered meningiomas. J Neurosurg 110(4):675–684CrossRefGoogle Scholar
  8. 8.
    Islim AI, Mohan M, Moon RDC, Srikandarajah N, Mills SJ, Brodbelt AR, Jenkinson MD (2019) Incidental intracranial meningiomas: a systematic review and meta-analysis of prognostic factors and outcomes. J Neuro-Oncol 142:211–221CrossRefGoogle Scholar
  9. 9.
    Jadid KD, Feychting M, Höijer J, Hylin S, Kihlström L, Mathiesen T (2015) Long-term follow-up of incidentally discovered meningiomas. Acta Neurochir 157:225–230CrossRefGoogle Scholar
  10. 10.
    Kasuya H, Kubo O, Tanaka M, Amano K, Kato K, Hori T (2006) Clinical and radiological features related to the growth potential of meningioma. Neurosurg Rev 29:293–297CrossRefGoogle Scholar
  11. 11.
    Lee EJ, Kim JH, Park ES, Kim YH, Lee JK, Hong SH, Cho YH, Kim CJ (2017) A novel weighted scoring system for estimating the risk of rapid growth in untreated intracranial meningiomas. J Neurosurg:1–10Google Scholar
  12. 12.
    Lee EJ, Park JH, Park ES, Kim JH (2017) “Wait-and-see” strategies for newly diagnosed intracranial meningiomas based on the risk of future observation failure. World Neurosurg.
  13. 13.
    Nakamura M, Roser F, Michel J, Jacobs C, Samii M (2003) The natural history of incidental meningiomas. Neurosurgery 53:62–71CrossRefGoogle Scholar
  14. 14.
    Nakasu S, Nakasu Y, Fukami T, Jito J, Nozaki K (2011) Growth curve analysis of asymptomatic and symptomatic meningiomas. J Neuro-Oncol 102:303–310CrossRefGoogle Scholar
  15. 15.
    Niiro M, Yatsushiro K, Nakamura K, Kawahara Y, Kuratsu JI (2000) Natural history of elderly patients with asymptomatic meningiomas. J Neurol Neurosurg Psychiatry 68:25–28CrossRefGoogle Scholar
  16. 16.
    Olayinka D, Yuen C, Castillo L et al (2018) Incidental meningiomas: validation of a novel scoring system to stratify risk for progression. J Clin Oncol 36(15_suppl).
  17. 17.
    Olivero WC, Lister JR, Elwood PW (1995) The natural history and growth rate of asymptomatic meningiomas: a review of 60 patients. J Neurosurg 83:222–224CrossRefGoogle Scholar
  18. 18.
    Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C et al (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro-Oncology 17(Suppl 4):iv1–iv62CrossRefGoogle Scholar
  19. 19.
    Oya S, Kim SH, Sade B, Lee JH (2011) The natural history of intracranial meningiomas. J Neurosurg 114:1250–1256CrossRefGoogle Scholar
  20. 20.
    Sughrue ME, Rutkowski MJ, Aranda D, Barani IJ, McDermott MW, Parsa AT (2010) Treatment decision making based on the published natural history and growth rate of small meningiomas a review and meta-analysis. J Neurosurg 113(5):1036–1042CrossRefGoogle Scholar
  21. 21.
    Turgut M, Ozcan OE, Benli K, Ozgen T, Gürcay O, Bertan V, Erbengi A, Sağlam S (1996) Factors affecting morbidity and mortality following surgical intervention in patients with intracranial meningioma. Aust N Z J Surg 66:144–150CrossRefGoogle Scholar
  22. 22.
    Yano S, Kuratsu J, Kumamoto Brain Tumor Research G (2006) Indications for surgery in patients with asymptomatic meningiomas based on an extensive experience. J Neurosurg 105(4):538–543CrossRefGoogle Scholar
  23. 23.
    Yoneoka Y, Fujii Y, Tanaka R (2000) Growth of incidental meningiomas. Acta Neurochir 142:507–511CrossRefGoogle Scholar
  24. 24.
    Zeng L, Liang P, Jiao J, Chen J, Lei T (2015) Will an asymptomatic meningioma grow or not grow? A meta-analysis. J Neurol Surg A 76:341–347CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2019

Authors and Affiliations

  • Ferran Brugada-Bellsolà
    • 1
    Email author
  • Pilar Teixidor Rodríguez
    • 1
  • Ana Rodríguez-Hernández
    • 1
  • Roser Garcia-Armengol
    • 1
  • Manel Tardáguila
    • 1
  • Antonio González-Crespo
    • 1
  • Carlos J. Domínguez
    • 1
  • Jordi M. Rimbau
    • 1
  1. 1.Department of Neurological SurgeryGermans Trias i Pujol University HospitalBarcelonaSpain

Personalised recommendations